NOVELION THERAPEUTICS INC. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Unaudited Condensed Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q3 FY2015 As of Sep 30, 2015	Q2 FY2015 As of Jun 30, 2015	Q1 FY2015 As of Mar 31, 2015	Q4 FY2014 As of Dec 31, 2014	Q3 FY2014 As of Sep 30, 2014	Q2 FY2014 As of Jun 30, 2014
Assets
Current assets:
Accounts receivable, net of allowances for doubtful accounts (Notes 4)
Investment (Note 2(a))
Restricted cash
Cash and cash equivalents
Accounts receivable, net
Contingent consideration - current (Notes 10, 14)
Loan receivable (Note 2(a))
Income taxes receivable
Deferred income tax assets - current (Note 13)
Inventories - current
Inventories - current
Insurance proceeds receivable
Prepaid expenses and other current assets
Total current assets

Inventories - non-current
Property and equipment, net
Deferred income tax assets - non-current (Note 13)
Accounts receivable - non-current (Note 16)
Intangible assets, net
Other non-current assets
Total assets

Liabilities and shareholders’ deficit
Current liabilities:
Accounts payable
Accrued liabilities
Accrued restructuring charge (Note 11)
Provision for legal settlement
Provision for legal settlement - current
Deferred revenue
Short-term debt
Convertible notes, net
Provision for legal settlements - current
Total current liabilities

Long-term debt
Convertible notes, net
Uncertain tax position liabilities, net (Note 13)
Provision for legal settlement - non-current
Provision for legal settlements - non-current
Other non-current liabilities
Total liabilities
Shareholders’ deficit:
Authorized 5,000,000 first preference shares without par value, issuable in series
Common shares, without par value, 100,000 shares authorized; 19,043 and 19,017 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
Additional paid-in-capital
Accumulated deficit
Accumulated other comprehensive income
Total shareholders’ deficit
Total liabilities and shareholders’ deficit

Comments